Peptide SS 31

Peptide ss 31 (also known as Elamipretide, original code name MTP-131/Bendavia) is one of the most representative candidate molecules in a class of "mitochondrial-targeting tetrapeptides," evolved from the aromatic-cationic peptide (SS peptide) family proposed by the Szeto-Schiller team. With cardiolipin (CL) as its core target, it improves energy metabolism and oxidative stress by remodeling the mitochondrial inner membrane microenvironment and electron transport chain (ETC) organization. It has been extensively studied in models of multi-system ischemia-reperfusion, mitochondrial diseases, and age-related degenerative diseases, as well as in early clinical trials.

Shaanxi Medibridge Biotech Co., Ltd. is your trusted peptide partner for academia and research labs worldwide. We supply research‑use‑only peptide raw materials with rigorous quality control, responsive support, and dependable lead times. Our Elamipretide (SS‑31/MTP‑131, Bendavia) is available at ≥99.78% purity, with clear documentation and flexible batch sizes to fit your study needs.

1.Mitochondria‑related disorders: Primary mitochondrial myopathies and Barth syndrome (defective cardiolipin remodeling) - an etiology‑directed arena where mechanism and disease biology align closely.
2.Cardiovascular–renal: Ischemia–reperfusion injury, heart failure, perioperative organ protection, and acute kidney injury - with emphasis on stress resilience and preservation of organ function.
3.Ophthalmology and neurodegeneration: Dry age‑related macular degeneration (AMD), optic neuropathies, and exploratory work in Parkinson's and Alzheimer's disease - leveraging bioenergetic support and membrane‑lipid homeostasis as entry points.

4.Overall research signal: Benefits are most evident under high‑stress conditions, marked mitochondrial dysfunction, or disrupted cardiolipin balance. The magnitude of effect varies by indication and endpoint (functional scales, exercise capacity, visual function, organ volumetrics/structural metrics).

1.In vitro: typical working range 10 nM–1 μM; prioritize stress, ischemia–reperfusion, or mitochondrial injury models to resolve differences.
2.In vivo: use acute dosing to capture protective effects, and chronic dosing to track gradual structure–function recovery.
3.Readouts: include mitochondrial coupling (OCR, RCR), lipid peroxidation markers, cristae ultrastructure, and electrophysiology/muscle strength/exercise capacity or organ‑specific functional measures.
4.Controls and conditions: temperature, nutritional status, oxygen tension, and calcium load strongly influence mitochondrial metrics-match controls and batches rigorously.